Cancer Treatment Centers of America

Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress

Retrieved on: 
Wednesday, October 25, 2023
Bone pain, Research, Plasma, Clinical trial, AAV, DBS, Biomarker, AST, Congress, Liver, Cancer Treatment Centers of America, CEST, Cell, Enzyme replacement therapy, White blood cell, Tissue, Gene, Glucocerebrosidase, Blood, ESGCT, Gaucher's disease, Safety, European Society for Primary Immunodeficiencies, Lysosome, ALT, Pharmaceutical industry, Patient

LONDON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease, show a substantial reduction of glucosylsphingosine (lyso-Gb1) levels in the blood of the first patient treated with FLT201. Lyso-Gb1 is a well-established biomarker of clinical response in Gaucher disease, with reductions in lyso-Gb1 correlating with positive clinical outcomes. These data are being highlighted in an oral presentation at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress held in Brussels, Belgium.

Key Points: 
  • Lyso-Gb1 is a well-established biomarker of clinical response in Gaucher disease, with reductions in lyso-Gb1 correlating with positive clinical outcomes.
  • These data are being highlighted in an oral presentation at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress held in Brussels, Belgium.
  • Reduction in lyso-Gb1 in the blood is strongly correlated with improvement in clinical outcomes in Gaucher disease.
  • The presentation entitled “Results from GALILEO-1, a First-In-Human Clinical Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1” is part of a session taking place from 14:30-16:30 CEST (8:30-10:30 a.m.

Trish Shucoski Named BayCare's Incoming Chief Nurse Executive

Retrieved on: 
Monday, October 2, 2023
Farmingdale State College, MSN, Nursing, State university system, Drexel University College of Medicine, Drexel University, DNP, Cancer Treatment Centers of America, Master of Science, Villanova University, Jefferson Health, Cooper University Hospital, Patient, Nassau Community College, CNE, BayCare Ballpark, RN, Chamberlain University, Health, Science

CLEARWATER, Fla., Oct. 2, 2023 /PRNewswire/ -- BayCare announced today that Patricia "Trish" Shucoski, DNP, MSN, RN, NEA-BC, will be its next Chief Nurse Executive (CNE), leading a corps of more than 10,550 nurses and nursing support staff when she assumes the role in December.

Key Points: 
  • CLEARWATER, Fla., Oct. 2, 2023 /PRNewswire/ -- BayCare announced today that Patricia "Trish" Shucoski, DNP, MSN, RN, NEA-BC, will be its next Chief Nurse Executive (CNE), leading a corps of more than 10,550 nurses and nursing support staff when she assumes the role in December.
  • Shucoski currently serves as BayCare's vice president of customer access and operational excellence.
  • Shucoski is a nurse with nearly 20 years of experience as a health care leader and holds a doctorate in nursing practice.
  • As a registered nurse in New Jersey and Pennsylvania, Trish worked for both Cancer Treatment Centers of America, where she was chief nurse, and Hahnemann University Hospital/Tenet Healthcare.

Mercy Names Dana Haynie of Oklahoma to Lead Cancer Services

Retrieved on: 
Monday, August 21, 2023
Heart, Mayo Clinic, Life, National Research Corporation, Marketing, Elective surgery, Pharmacy, GRAIL (company), Accountable care organization, Health, Cancer, Cure, Woman, Research, Multimedia, CTCA, Cancer Treatment Centers of America, Hospital, Neuroscience, Patient, Physician, Haynie, Medicine, Diagnosis, GI, Breast cancer, Nursing, Mercy

ST. LOUIS and OKLAHOMA CITY, Aug. 21, 2023 /PRNewswire/ -- Mercy has named a new leader to grow and transform cancer services for patients in Arkansas, Kansas, Missouri and Oklahoma.

Key Points: 
  • ST. LOUIS and OKLAHOMA CITY, Aug. 21, 2023 /PRNewswire/ -- Mercy has named a new leader to grow and transform cancer services for patients in Arkansas, Kansas, Missouri and Oklahoma.
  • Dana Haynie will serve as Mercy's service line president for cancer care.
  • Haynie was previously president and chief executive officer at Cancer Treatment Centers of America (CTCA) in Tulsa, Oklahoma, part of a national network of hospitals that specialized in the treatment of patients fighting complex or advanced-stage cancer.
  • Haynie will collaborate with Mercy physicians and leaders across Arkansas, Missouri, Kansas and Oklahoma to align, further develop, and grow these services.

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Retrieved on: 
Friday, May 26, 2023
MSD, Senior, Hepatocellular carcinoma, Pharming, Sunitinib, Survival, Head, DO, Cancer, Patient, Stomatitis, Risk, Merck, Fatigue, Texas Oncology, Diarrhea, Pembrolizumab, FACP, Research, Lung cancer, Merck & Co., Hypertension, LEAP, HIV disease progression rates, Esophageal cancer, Abstract, Death, Apoptosis, Lenvatinib, Overalls, PFS, Eisai, CR, Stomach, ORR, Acral lentiginous melanoma, Arm, Progression-free survival, RCC, CI, OS, Drug, Trae tha Truth, Hypothyroidism, ASCO, Central Time Zone, American Society of Clinical Oncology, Cancer Treatment Centers of America, Physician, Annual general meeting, Nausea, Society, Pharmaceutical industry, EU

After four years of follow-up, LENVIMA plus KEYTRUDA maintained a clinically meaningful OS benefit versus sunitinib, reducing the risk of death by 21% (HR=0.79 [95% CI, 0.63-0.99]).

Key Points: 
  • After four years of follow-up, LENVIMA plus KEYTRUDA maintained a clinically meaningful OS benefit versus sunitinib, reducing the risk of death by 21% (HR=0.79 [95% CI, 0.63-0.99]).
  • The 24- and 36-month estimated OS rates were 80.4% and 66.4% for LENVIMA plus KEYTRUDA versus 69.6% and 60.2% for sunitinib, respectively.
  • Grade ≥3 treatment-related adverse events (TRAE) occurred in 74.1% of patients who received LENVIMA plus KEYTRUDA versus 60.3% of patients who received sunitinib.
  • These findings reinforce the important role of LENVIMA plus KEYTRUDA as a first-line standard of care treatment option for patients with advanced renal cell carcinoma."

Technology Innovator ShiftKey Taps New Board Members, Including Southwest Airlines President & CEO

Retrieved on: 
Wednesday, August 2, 2023
Technology, General Health, Professional Services, Hospitals, Small Business, Health, Health Technology, Apps, Applications, Other Technology, Software, Other Professional Services, Internet, Human Resources, Outsourcing Business, Data Management, Practice Management, Consulting, Olive, Liveops, Luminate, IPO, Lightning, Sanger, Borgen, Corporate services, Engineering, Lightning Network, Health care, Netscape, Communication, Southwest Airlines, Partner (business rank), United Automotive Technologies, For-profit education, Envision Healthcare, Jordan, Veteran, Strategic planning, Everingham, Integrating the Healthcare Enterprise, Cancer Treatment Centers of America, Organization, Strategic management, Staples, Partner, Yahoo!, Fortune 500, DaVita Inc., AirTran Airways, Culture, SVP, Real estate, Management, Lightspark

ShiftKey , a leading technology company transforming the future of work, today announced four new board members: Luis Borgen, former chief financial officer, athenahealth; James Everingham, co-founder and senior vice president of engineering, Lightspark; Bob Jordan, president & CEO, Southwest Airlines; and William “Bill” Sanger, managing partner, Sanger Holdings.

Key Points: 
  • ShiftKey , a leading technology company transforming the future of work, today announced four new board members: Luis Borgen, former chief financial officer, athenahealth; James Everingham, co-founder and senior vice president of engineering, Lightspark; Bob Jordan, president & CEO, Southwest Airlines; and William “Bill” Sanger, managing partner, Sanger Holdings.
  • “I am thrilled to welcome Luis, James, Bob and Bill to the ShiftKey Board.
  • Bob Jordan serves as President & CEO at Southwest Airlines, with deep experience in driving scalable technology, leading transformative integrations and building strong teams with nationally recognized customer service.
  • Most recently, he served as Southwest Airlines' Executive Vice President Corporate Services, providing Executive Leadership for Southwest's world-renowned People and Culture, training at Southwest Airlines University, Diversity, Equity, & Inclusion efforts, and Communications & Outreach Teams.

Oncology Care Partners Names Dr. Chevon Rariy Chief Health Officer

Retrieved on: 
Thursday, July 13, 2023
Oncology Care Model, Endocrinology, University, Internal medicine, Amazon (company), University of Pittsburgh Medical Center, Quality of life, Research, SVP-24, Government, Harvard Medical School, Cancer Treatment Centers of America, Amazon, Cancer, City, OCP, Publication, Brigham, Digital health, MD, Patient, Op-ed, Machine learning, Artificial intelligence, Hospital, Health, SVP, Brigham and Women's Hospital, Takeda Pharmaceutical Company, Nursing, Medical imaging

NASHVILLE, Tenn., July 13, 2023 /PRNewswire/ -- Oncology Care Partners (OCP), an oncology provider built solely to provide value-based care, today announces the appointment of Chevon Rariy, MD as Chief Health Officer—further elevating its telehealth and digital health capabilities to enhance both patient and provider experience.

Key Points: 
  • NASHVILLE, Tenn., July 13, 2023 /PRNewswire/ -- Oncology Care Partners (OCP), an oncology provider built solely to provide value-based care, today announces the appointment of Chevon Rariy, MD as Chief Health Officer—further elevating its telehealth and digital health capabilities to enhance both patient and provider experience.
  • "I am thrilled to join the dynamic team at OCP, where we are revolutionizing oncology care through a patient-centric value-based approach," said Chevon Rariy, MD.
  • "We are beyond excited to have Dr. Rariy join our senior leadership team," said Erich Mounce, CEO, Oncology Care Partners.
  • With its first two practices across three locations in Phoenix and Miami, Oncology Care Partners is committed to advancing value-based care in oncology nationwide by bringing high-touch, whole-person care that enhances the patient experience across its medical oncology practices.

Experience Luxurious Suburban Living at Alta Ashley Park as Wood Partners Opens Newest Apartment Community in Newnan, Georgia

Retrieved on: 
Tuesday, June 27, 2023
Ashley Park, University, Delta Air Lines, Tanning, Wood, The Home Depot, Cancer Treatment Centers of America, Huron Valley School District, AAMCO, Coca-Cola, Ruth Hill, Hotel

Located just south of Atlanta, Alta Ashley Park provides the ideal work-live-play setting for young professionals looking to strike an even balance between city life and suburban charm.

Key Points: 
  • Located just south of Atlanta, Alta Ashley Park provides the ideal work-live-play setting for young professionals looking to strike an even balance between city life and suburban charm.
  • "We are thrilled to announce the grand opening of Alta Ashley Park in the beautiful historic city of Newnan, Georgia," said Bennett Sands, Managing Director at Wood Partners.
  • "This luxurious residential community offers a perfect blend of comfort and convenience, providing an exceptional living experience for our residents just outside Atlanta.
  • Alta Ashley Park offers 269 apartment homes ranging from one-, two-, and three-bedroom layouts to full carriage homes.

The V Foundation for Cancer Research Announces the First Class of A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research

Retrieved on: 
Tuesday, June 27, 2023
Pancreatic cancer, Tobacco Products Scientific Advisory Committee, VCU Massey Cancer Center, Male, University, Mohammed V Foundation for Solidarity, Cancer research, COVID-19, NYU, Cancer, Jim Valvano, CDK7, Woman, Research, Salk Institute for Biological Studies, RNA, Assistant, Science, Cooper University Hospital, UCSF, Patient, Cancer Treatment Centers of America, Engineering, Melanoma, Dartmouth Cancer Center, Washington University School of Medicine, University of British Columbia, Ovarian cancer, Aichi M6A, Female, Prostate cancer, Dana–Farber Cancer Institute, Pharmaceutical industry, Nursing, Vaccine, Birth control, Doctor of Philosophy, MD

CARY, N.C., June 27, 2023 /PRNewswire/ -- The V Foundation for Cancer Research, a premier cancer research charity, proudly announces the first recipients of A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research. This landmark initiative is helping to counteract longstanding gender disparities in research by investing $8 million in the groundbreaking work of 11 women scientists leading the charge in cancer research.

Key Points: 
  • CARY, N.C., June 27, 2023 /PRNewswire/ -- The V Foundation for Cancer Research, a premier cancer research charity, proudly announces the first recipients of A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research.
  • We are not only advancing vital cancer research, but we're working to encourage more women to pursue careers in science.
  • The setbacks endured throughout the pandemic will have long-term for women in cancer research.
  • Recognizing these disparities, the V Foundation for Cancer Research developed A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research to amplify female representation and encourage more women-led breakthroughs in this field.

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Retrieved on: 
Thursday, May 25, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Senior, Hepatocellular carcinoma, Pharming, Sunitinib, Survival, Everolimus, RECIST, Head, DO, Cancer, Patient, Stomatitis, Risk, NYSE, Fatigue, Texas Oncology, Diarrhea, Pembrolizumab, FACP, MRK, Research, Lung cancer, Merck & Co., Hypertension, LEAP, HIV disease progression rates, IMDC, Esophageal cancer, Memorial Sloan Kettering Cancer Center, PD-1, Abstract, Death, Safety, Lenvatinib, Overalls, Multimedia, PFS, CR, Stomach, ORR, Acral lentiginous melanoma, IRC, Progression-free survival, RCC, CI, OS, Drug, Trae tha Truth, MSKCC, Hypothyroidism, EDT, ASCO, American Society of Clinical Oncology, Cancer Treatment Centers of America, Physician, Quality of life (healthcare), Annual general meeting, Nausea, Interpretation, Society, Pharmaceutical industry, Dietary supplement, Merck, EU, Eisai

After four years of follow-up, KEYTRUDA plus LENVIMA maintained a clinically meaningful OS benefit versus sunitinib, reducing the risk of death by 21% (HR=0.79 [95% CI, 0.63-0.99]).

Key Points: 
  • After four years of follow-up, KEYTRUDA plus LENVIMA maintained a clinically meaningful OS benefit versus sunitinib, reducing the risk of death by 21% (HR=0.79 [95% CI, 0.63-0.99]).
  • The 24- and 36-month estimated OS rates were 80.4% and 66.4% for KEYTRUDA plus LENVIMA versus 69.6% and 60.2% for sunitinib, respectively.
  • Results from the final pre-specified OS analysis were consistent with the superior results versus sunitinib from the primary OS analysis of the CLEAR/KEYNOTE-581 trial.
  • Grade ≥3 treatment-related adverse events (TRAE) occurred in 74.1% of patients who received KEYTRUDA plus LENVIMA versus 60.3% of patients who received sunitinib.

Recovery Centers of America Calls for End to Stigma During Mental Health Awareness Month

Retrieved on: 
Thursday, May 4, 2023
Learning, RCA, Substance Abuse, Depression, Sleep, Mirror Lake Recovery Center, Education, Life, Friends, Sleep deprivation, Anxiety, Mental health, DSM-IV codes, Grain boundary strengthening, Psychotherapy, National Survey on Drug Use and Health, Vegetable, Mental Health Awareness Month, Mental, Grief, MAT, Eating, Nursing, Cancer Treatment Centers of America, Physical fitness, Addiction, Mental health service, Memory, Irritability, Fatigue, Substance abuse, Health

King of Prussia, PA, May 04, 2023 (GLOBE NEWSWIRE) -- Recovery Centers of America (RCA), a healthcare network of substance use disorder treatment facilities on the East Coast and in the Midwest, today kicked off May as Mental Health Awareness Month with a call to end the stigma associated with mental health issues, and tips to help anyone – including those in recovery – improve their mental and emotional well-being.

Key Points: 
  • King of Prussia, PA, May 04, 2023 (GLOBE NEWSWIRE) -- Recovery Centers of America (RCA), a healthcare network of substance use disorder treatment facilities on the East Coast and in the Midwest, today kicked off May as Mental Health Awareness Month with a call to end the stigma associated with mental health issues, and tips to help anyone – including those in recovery – improve their mental and emotional well-being.
  • “Recovery Centers of America sees first-hand how prevalent mental health issues are – both as a root of substance abuse and a result of it.
  • About 53% (or 9 million adults) received either substance use treatment at a specialty facility or mental health services, though 84% received only mental health services, according to the survey.
  • If you or your loved one are struggling with addiction or mental health issues associated with addiction, the staff at Recovery Centers of America is here to help.